Compound profile
Dihexa
EmergingAlso known as: N-hexanoic-Tyr-Ile-(6)aminohexanoic amide · PNB-0408
A small, orally active molecule derived from angiotensin IV, developed as a potential cognition-enhancing compound by potentiating HGF/c-Met signaling involved in synapse formation. Studied only in animal models; its foundational 2013 paper has since received a formal journal Notice of Concern, adding an important caveat to an already early-stage evidence base.
Overview
Dihexa was developed in the late 2000s and early 2010s by Joseph Harding and colleagues at Washington State University, building on years of research into angiotensin IV and its effects on memory in animal models. Rather than being a peptide fragment used directly, dihexa was chemically engineered to be small, stable, and orally bioavailable while preserving the procognitive activity researchers had observed with angiotensin IV-related peptides, addressing the practical problem that many peptide-based cognitive compounds break down too quickly or can't cross into the brain effectively when taken by mouth.
Its proposed mechanism centers on potentiating hepatocyte growth factor (HGF) signaling through the c-Met receptor, a pathway with a known role in synaptic development, rather than working through the classic angiotensin receptors most of that family of molecules use. In preclinical models, this was linked to increased dendritic spine density and new synapse formation, findings that generated real scientific interest as a potential approach to cognitive decline and dementia.
That interest, and dihexa's growing reputation in nootropic communities, needs to be weighed against two things: all of the supporting data comes from animal and cell studies, with no human trials published, and the foundational 2013 paper establishing much of its core pharmacology has since received a formal Notice of Concern from the publishing journal, an editorial flag indicating identified issues with the original publication that readers should be aware of when evaluating the strength of that evidence.
Mechanism (plain language)
Proposed to potentiate hepatocyte growth factor (HGF) signaling through the c-Met receptor, a pathway distinct from classic angiotensin receptors, which in preclinical models is linked to increased dendritic spine density and new synapse formation.
How it works
Rather than acting through the angiotensin receptors most related compounds use, dihexa is proposed to work by potentiating HGF binding to and activation of its receptor, c-Met, a receptor tyrosine kinase with known roles in cell growth, tissue repair, and, specifically in neurons, synaptic development. In cultured hippocampal tissue, researchers reported dihexa drove new dendritic spine formation and synaptogenesis at extremely low concentrations, a finding described in some of the literature as far more potent on a molar basis than BDNF, the brain's own major growth factor for synaptic plasticity, though that comparison is specific to one in vitro synaptogenesis assay and does not mean dihexa broadly outperforms BDNF's many other functions.
In animal behavioral studies, this proposed synapse-building activity was linked to improved performance in memory tasks in both scopolamine-impaired and naturally aged rats, the basis for dihexa's reputation as a potential procognitive or antidementia compound. All of this evidence comes from preclinical models; the intracellular signaling cascade and its downstream effects on cognition have not been verified in any published human study.
What research suggests
Animal studies report improved performance on memory tasks and increased markers of synaptic plasticity with dihexa administration. This evidence is entirely preclinical, and the foundational 2013 paper describing its core pharmacology has since received a formal journal Notice of Concern.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Increased synapse formation in preclinical models
Cell-culture studies on hippocampal tissue reported dihexa drove new dendritic spine formation and synaptogenesis at very low concentrations, the basis for its reputation as a potential procognitive compound.
Improved memory task performance in animal studies
In rat models, including scopolamine-impaired and naturally aged animals, dihexa administration was linked to improved performance on memory tasks, and a separate 2021 study reported cognitive improvement in an Alzheimer's-model mouse.
Uncertainties & risks
No human trials of dihexa have been conducted or published, so there is no human safety, dosing, or efficacy data of any kind. The 2013 paper most frequently cited as establishing dihexa's mechanism and effects received a Notice of Concern from the Journal of Pharmacology and Experimental Therapeutics, which readers should weigh when assessing how solid the existing evidence base actually is.
Dihexa's evidence base needs two important caveats that are often left out of enthusiastic write-ups: first, every finding comes from rodent or cell-culture studies, with no human trial ever conducted, so claims about cognitive enhancement in people are extrapolations rather than demonstrated effects. Second, and less commonly mentioned, the foundational 2013 paper describing dihexa's synaptogenic potency and its behavioral effects in rats received a formal Notice of Concern from the publishing journal after its original publication, a flag that does not necessarily mean the findings are wrong but does mean they warrant additional scrutiny rather than being taken at face value. Combined with the complete absence of human data, dihexa sits meaningfully earlier in the evidence pipeline than its popularity in nootropic and longevity circles might suggest.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.